OncoMatch/Clinical Trials/NCT07789717
Pharmacopuncture for Aromatase Inhibitor Induced Arthralgia (AIA)
Is NCT07789717 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for breast cancer.
This is a pragmatic pilot trial designed to compare and evaluate the efficacy, safety, and cost-effectiveness of pharmacopuncture treatment versus a control group in aromatase inhibitor-induced arthralgia patients with breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Required: Stage LOCALIZED, III
Excluded: Stage IV
Individuals diagnosed with localized or limited-stage hormone receptor-positive breast cancer; Patients with Stage IV (metastatic) breast cancer [excluded]
Demographics
Prior therapy
Must have received: aromatase inhibitor
require the use of aromatase inhibitors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07789717 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received aromatase inhibitor.
What disease stage is eligible?
Stage LOCALIZED or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 19 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages